After the successful completion of the phase 1 trial, which determined both the safety and correct dosage of the combination of drugs, Solving Kids’ Cancer launched a phase II trial to test Nifurtimox in more children with neuroblastoma, and also in children with medulloblastoma.

Project Title: Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma
Researcher: Giselle Sholler, MD
Institution:  NMTRC Institutions
Study Type: Phase II clinical trial
Status: Ongoing

Drugs used for another disease are occasionally found to work against cancer, and sometimes this discovery happens accidently.  This was the case with Nifurtimox, a drug used to treat a parasitic disease called Chagas Disease. One of the co-founders of Solving Kids’ Cancer had read a case study reporting how Nifurtimox reduced the tumor size in a child with neuroblastoma that did not respond to chemotherapy. After the successful completion of the phase I trial, which determined both the safety and correct dosage of the combination of drugs, Solving Kids’ Cancer launched a phase II trial to test Nifurtimox in more children with neuroblastoma, as well as in children with medulloblastoma, a type of brain tumor. This phase II clinical trial is now available at over 13 cancer centers in the U.S.

To learn more about this trial, visit clinicaltrials.gov